NCT07355075 Phase 2, phase 3 Recruiting
A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema) Study sponsor: Turn Therapeutics
Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.
Changes Study details Primary completion 2027-01-20 Estimated
Enrollment · participants 190 Estimated
Source updated 2026-09-04 Last update listed in the registry record
Version history
Changes to this trial Last 12 months
Posted 2026-09-04 · 4 fields changed
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before Measure: Change in Investigator Global Assessment (IGA) at Week 8
+ After Measure: vIGA-AD Success at Week 4
Measure: EASI-75 at Week 4
Measure: EASI-90 at Week 8
Measure: EASI-100 at Week 8
Planned enrollment increased by 80 participants
− Before 110 participants (planned)
+ After 190 participants (planned)
Primary completion date changed
Check registry source
Posted 2026-05-18 · 3 fields changed
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before Measure: Change in Eczema Area and Severity (EASI)
+ After Measure: Change in Investigator Global Assessment (IGA ) at Week 8
Planned enrollment increased by 10 participants
− Before 100 participants (planned)
+ After 110 participants (planned)
Primary completion date changed
Check registry source
This database covers selected trials and recorded edits. Some past edits may be missing, and saved text about the main study measures (endpoints) may be shortened. Check the original registry record when a detail matters. Read our methodology
Trial